141 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Biotechs: Still Well Placed For More Gains https://seekingalpha.com/article/4148492-biotechs-still-well-placed-gains?source=feed_all_articles Feb 20, 2018 - Sharp market correction triggered by interest rate concerns creates opportunities.Market transitions into a more typical rally and pullback mode, with a continued firm uptrend.Biotech stocks are exper
Market Conflict Next Week: What To Watch https://seekingalpha.com/article/4148094-market-conflict-next-week-watch?source=feed_all_articles Feb 19, 2018 - After a wild and volatile 2 weeks, what to think about for the short trading week to come.The multiple conflicts affecting the markets.2 chart indicators to be aware of.My thoughts and stocks to watch
JF's Core Biotech Buys Edition 1 Volume 3: 2 New Purchases, Plus Thoughts On Portfolio Management And Performance https://seekingalpha.com/article/4148052-jfs-core-biotech-buys-edition-1-volume-3-2-new-purchases-plus-thoughts-portfolio-management?source=feed_all_articles Feb 19, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I provide an early performance update and
Options Traders Expect Huge Moves in Array BioPharma (ARRY) Stock http://www.zacks.com/stock/news/292693/options-traders-expect-huge-moves-in-array-biopharma-arry-stock?cid=CS-ZC-FT-292693 Feb 16, 2018 - Array BioPharma (ARRY) needs investors to pay close attention to the stock based on moves in the options market lately.
EcoR1 Capital, LLC Buys Dicerna Pharmaceuticals Inc, Apellis Pharmaceuticals Inc, Macrogenics ... http://www.gurufocus.com/news/641665/ecor1-capital-llc-buys-dicerna-pharmaceuticals-inc-apellis-pharmaceuticals-inc-macrogenics-inc-sells-immunomedics-inc-marinus-pharmaceuticals-inc-tocagen-inc Feb 14, 2018 -
How to Uncover Institutional Buying http://www.zacks.com/commentary/149190/how-to-uncover-institutional-buying?cid=CS-ZC--149190 Feb 13, 2018 - How to Uncover Institutional Buying
JF's Core Biotech Buys Edition 1 Volume 2: How Market Turmoil Affects Long-Term Investors And Actions To Take https://seekingalpha.com/article/4145063-jfs-core-biotech-buys-edition-1-volume-2-market-turmoil-affects-long-term-investors-actions?source=feed_all_articles Feb 09, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I comment on recent market turmoil and ho
U.S. Biotech/Pharma Sector Daily Observations Letter: February 6, 2018 https://seekingalpha.com/article/4144085-u-s-biotech-pharma-sector-daily-observations-letter-february-6-2018?source=feed_all_articles Feb 07, 2018 - The broad U.S. market and the biotech sector rebounded today after hitting a key support level. Will the rebound sustain?Interpreting Array Biopharma's (ARRY) COLUMBUS OS data.Interpeting Allergan's o
ARRY: Stifel reits Buy http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20180207085615 Feb 07, 2018 - Stifel issues rating change for ARRY
Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results https://seekingalpha.com/article/4143836-daily-pharma-scoop-nabriva-pullback-gw-pharmaceuticals-makes-progress-contravir-announces?source=feed_sector_healthcare Feb 07, 2018 - Nabriva has a major catalyst coming up. GW Pharmaceuticals’ marketing application for Epidiolex accepted by EMA. ContraVir announces results from early stage study of Hep B candidate TXL.

Pages: 12345678910...15

<<<Page 5>